Spagyra

Spagyra, Inc. was a biotechnology company focused on the discovery and development of novel small molecule therapeutics for neurodegenerative disorders, with a primary emphasis on Alzheimer's disease. The company's core technology centered on the use of pharmacological chaperones designed to stabilize the native conformation of proteins, thereby preventing the misfolding and aggregation of amyloid-beta and tau. Founded by Dr. Robert Friedland, a prominent neurologist, the company aimed to translate academic research from the University of Louisville into clinical applications that could halt disease progression. Although the company is no longer active, its approach to protein stabilization remains a significant area of interest in the field of dementia research.